Denali Therapeutics Inc. (NASDAQ: DNLI) Stock Competitors & Peer Comparison
See DNLI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DNLI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DNLI | $24.17 | +4.41% | 3.8B | -8.39 | -$2.88 | N/A |
| VRTX | $478.71 | +1.70% | 121.5B | 25.44 | $18.82 | N/A |
| REGN | $760.66 | +0.19% | 78.3B | 16.67 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $844.50 | +1.65% | 52.5B | 76.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $10.02 | +13.35% | 41.8B | -2.42 | -$4.15 | N/A |
| RVMD | $193.46 | +6.03% | 41.1B | -27.36 | -$7.07 | N/A |
| ONC | $323.01 | +2.94% | 34.5B | 72.26 | $4.47 | N/A |
| ALNY | $219.00 | -0.60% | 29.3B | 39.46 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
DNLI vs VRTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, VRTX has a market cap of 121.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while VRTX trades at $478.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas VRTX's P/E ratio is 25.44. In terms of profitability, DNLI's ROE is -0.52%, compared to VRTX's ROE of +0.21%. Regarding short-term risk, DNLI is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
DNLI vs REGN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, REGN has a market cap of 78.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while REGN trades at $760.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas REGN's P/E ratio is 16.67. In terms of profitability, DNLI's ROE is -0.52%, compared to REGN's ROE of +0.18%. Regarding short-term risk, DNLI is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
DNLI vs VRNA Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DNLI's ROE is -0.52%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, DNLI is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
DNLI vs ARGX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ARGX has a market cap of 52.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ARGX trades at $844.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ARGX's P/E ratio is 76.22. In terms of profitability, DNLI's ROE is -0.52%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, DNLI is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
DNLI vs SGEN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DNLI's ROE is -0.52%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DNLI is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
DNLI vs RVMDW Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RVMDW trades at $10.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RVMDW's P/E ratio is -2.42. In terms of profitability, DNLI's ROE is -0.52%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, DNLI is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
DNLI vs RVMD Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RVMD has a market cap of 41.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RVMD trades at $193.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RVMD's P/E ratio is -27.36. In terms of profitability, DNLI's ROE is -0.52%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, DNLI is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
DNLI vs ONC Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ONC has a market cap of 34.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ONC trades at $323.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ONC's P/E ratio is 72.26. In terms of profitability, DNLI's ROE is -0.52%, compared to ONC's ROE of +0.12%. Regarding short-term risk, DNLI is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
DNLI vs ALNY Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ALNY has a market cap of 29.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ALNY trades at $219.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ALNY's P/E ratio is 39.46. In terms of profitability, DNLI's ROE is -0.52%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, DNLI is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
DNLI vs ROIV Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ROIV trades at $34.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ROIV's P/E ratio is -35.55. In terms of profitability, DNLI's ROE is -0.52%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, DNLI is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
DNLI vs INCY Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while INCY trades at $120.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas INCY's P/E ratio is 16.21. In terms of profitability, DNLI's ROE is -0.52%, compared to INCY's ROE of +0.30%. Regarding short-term risk, DNLI is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
DNLI vs BNTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while BNTX trades at $91.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas BNTX's P/E ratio is -19.77. In terms of profitability, DNLI's ROE is -0.52%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, DNLI is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check BNTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
DNLI vs MRNA Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, MRNA has a market cap of 22.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while MRNA trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas MRNA's P/E ratio is -6.99. In terms of profitability, DNLI's ROE is -0.52%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, DNLI is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check MRNA's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
DNLI vs UTHR Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while UTHR trades at $518.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas UTHR's P/E ratio is 19.15. In terms of profitability, DNLI's ROE is -0.52%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DNLI is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check UTHR's competition here
Insmed Incorporated (NASDAQ: INSM)
DNLI vs INSM Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while INSM trades at $98.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas INSM's P/E ratio is -17.17. In terms of profitability, DNLI's ROE is -0.52%, compared to INSM's ROE of -1.30%. Regarding short-term risk, DNLI is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
DNLI vs BGNE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DNLI's ROE is -0.52%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, DNLI is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
DNLI vs DNA-WT Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DNLI's ROE is -0.52%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, DNLI is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
DNLI vs GMAB Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, GMAB has a market cap of 17.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while GMAB trades at $29.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas GMAB's P/E ratio is 20.88. In terms of profitability, DNLI's ROE is -0.52%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, DNLI is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
DNLI vs NBIX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while NBIX trades at $166.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas NBIX's P/E ratio is 24.00. In terms of profitability, DNLI's ROE is -0.52%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, DNLI is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
DNLI vs JAZZ Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, JAZZ has a market cap of 16.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while JAZZ trades at $261.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas JAZZ's P/E ratio is 20.34. In terms of profitability, DNLI's ROE is -0.52%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, DNLI is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
DNLI vs BBIO Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, BBIO has a market cap of 16.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while BBIO trades at $82.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas BBIO's P/E ratio is -21.94. In terms of profitability, DNLI's ROE is -0.52%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, DNLI is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
DNLI vs ASND Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ASND has a market cap of 15.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ASND trades at $244.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ASND's P/E ratio is -101.07. In terms of profitability, DNLI's ROE is -0.52%, compared to ASND's ROE of -56.42%. Regarding short-term risk, DNLI is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
DNLI vs EXEL Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while EXEL trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas EXEL's P/E ratio is 16.77. In terms of profitability, DNLI's ROE is -0.52%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, DNLI is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check EXEL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
DNLI vs ARWR Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ARWR has a market cap of 12.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ARWR trades at $89.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ARWR's P/E ratio is -41.67. In terms of profitability, DNLI's ROE is -0.52%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, DNLI is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ARWR's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
DNLI vs KRTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DNLI's ROE is -0.52%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DNLI is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
DNLI vs BMRN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, BMRN has a market cap of 11.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while BMRN trades at $60.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas BMRN's P/E ratio is 29.19. In terms of profitability, DNLI's ROE is -0.52%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, DNLI is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
DNLI vs MDGL Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while MDGL trades at $507.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas MDGL's P/E ratio is -39.65. In terms of profitability, DNLI's ROE is -0.52%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, DNLI is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
DNLI vs TECH Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas TECH's P/E ratio is 37.16. In terms of profitability, DNLI's ROE is -0.52%, compared to TECH's ROE of +0.05%. Regarding short-term risk, DNLI is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
DNLI vs RNAM Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DNLI's ROE is -0.52%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DNLI is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check RNAM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
DNLI vs SMMT Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, SMMT has a market cap of 11B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while SMMT trades at $13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas SMMT's P/E ratio is -8.60. In terms of profitability, DNLI's ROE is -0.52%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, DNLI is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check SMMT's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
DNLI vs AXSM Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, AXSM has a market cap of 10.9B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while AXSM trades at $212.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas AXSM's P/E ratio is -55.40. In terms of profitability, DNLI's ROE is -0.52%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, DNLI is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check AXSM's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
DNLI vs HALO Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, HALO has a market cap of 9.9B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while HALO trades at $83.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas HALO's P/E ratio is 18.02. In terms of profitability, DNLI's ROE is -0.52%, compared to HALO's ROE of +1.26%. Regarding short-term risk, DNLI is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
DNLI vs CYTK Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CYTK trades at $78.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CYTK's P/E ratio is -13.48. In terms of profitability, DNLI's ROE is -0.52%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, DNLI is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CYTK's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
DNLI vs KRYS Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while KRYS trades at $324.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas KRYS's P/E ratio is 43.42. In terms of profitability, DNLI's ROE is -0.52%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DNLI is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
DNLI vs RXDX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DNLI's ROE is -0.52%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DNLI is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
DNLI vs ABVX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ABVX trades at $125.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ABVX's P/E ratio is -65.62. In terms of profitability, DNLI's ROE is -0.52%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, DNLI is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
DNLI vs IONS Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while IONS trades at $55.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas IONS's P/E ratio is -32.02. In terms of profitability, DNLI's ROE is -0.52%, compared to IONS's ROE of -1.11%. Regarding short-term risk, DNLI is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
DNLI vs NUVL Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas NUVL's P/E ratio is -21.79. In terms of profitability, DNLI's ROE is -0.52%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DNLI is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check NUVL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
DNLI vs SYRE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, SYRE has a market cap of 9.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while SYRE trades at $104.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas SYRE's P/E ratio is -50.45. In terms of profitability, DNLI's ROE is -0.52%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, DNLI is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check SYRE's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
DNLI vs CRNX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CRNX trades at $83.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CRNX's P/E ratio is -16.35. In terms of profitability, DNLI's ROE is -0.52%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DNLI is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
DNLI vs PTGX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while PTGX trades at $135.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas PTGX's P/E ratio is -75.03. In terms of profitability, DNLI's ROE is -0.52%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, DNLI is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
DNLI vs IMGN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DNLI's ROE is -0.52%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DNLI is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check IMGN's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
DNLI vs PRAX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while PRAX trades at $310.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas PRAX's P/E ratio is -23.19. In terms of profitability, DNLI's ROE is -0.52%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, DNLI is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
DNLI vs KYMR Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, KYMR has a market cap of 8.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while KYMR trades at $104.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas KYMR's P/E ratio is -29.57. In terms of profitability, DNLI's ROE is -0.52%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, DNLI is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check KYMR's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
DNLI vs BPMC Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DNLI's ROE is -0.52%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, DNLI is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check BPMC's competition here
Alkermes plc (NASDAQ: ALKS)
DNLI vs ALKS Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ALKS trades at $49.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ALKS's P/E ratio is 52.28. In terms of profitability, DNLI's ROE is -0.52%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, DNLI is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ALKS's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
DNLI vs APGE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while APGE trades at $134.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas APGE's P/E ratio is -30.99. In terms of profitability, DNLI's ROE is -0.52%, compared to APGE's ROE of -0.33%. Regarding short-term risk, DNLI is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
DNLI vs CERE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, DNLI's ROE is -0.52%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DNLI is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
DNLI vs IMVT Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while IMVT trades at $39.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas IMVT's P/E ratio is -14.74. In terms of profitability, DNLI's ROE is -0.52%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, DNLI is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
DNLI vs PCVX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while PCVX trades at $54.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas PCVX's P/E ratio is -7.95. In terms of profitability, DNLI's ROE is -0.52%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, DNLI is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check PCVX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
DNLI vs TGTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, TGTX has a market cap of 7.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while TGTX trades at $48.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas TGTX's P/E ratio is 16.75. In terms of profitability, DNLI's ROE is -0.52%, compared to TGTX's ROE of +0.84%. Regarding short-term risk, DNLI is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
DNLI vs MTSR Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DNLI's ROE is -0.52%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, DNLI is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check MTSR's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
DNLI vs COGT Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, COGT has a market cap of 7.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while COGT trades at $42.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas COGT's P/E ratio is -20.30. In terms of profitability, DNLI's ROE is -0.52%, compared to COGT's ROE of -0.83%. Regarding short-term risk, DNLI is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check COGT's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
DNLI vs IBRX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while IBRX trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas IBRX's P/E ratio is -8.18. In terms of profitability, DNLI's ROE is -0.52%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, DNLI is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
DNLI vs RYTM Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RYTM trades at $105.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RYTM's P/E ratio is -33.80. In terms of profitability, DNLI's ROE is -0.52%, compared to RYTM's ROE of -2.01%. Regarding short-term risk, DNLI is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
DNLI vs MRUS Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DNLI's ROE is -0.52%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, DNLI is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
DNLI vs ACLX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DNLI's ROE is -0.52%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DNLI is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
DNLI vs RETA Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, DNLI's ROE is -0.52%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DNLI is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
DNLI vs ERAS Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ERAS trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ERAS's P/E ratio is -19.76. In terms of profitability, DNLI's ROE is -0.52%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, DNLI is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check ERAS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
DNLI vs MIRM Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, MIRM has a market cap of 6.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while MIRM trades at $104.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas MIRM's P/E ratio is -7.67. In terms of profitability, DNLI's ROE is -0.52%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, DNLI is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
DNLI vs BLTE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while BLTE trades at $157.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas BLTE's P/E ratio is -84.10. In terms of profitability, DNLI's ROE is -0.52%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, DNLI is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
DNLI vs CGON Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CGON trades at $71.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CGON's P/E ratio is -30.64. In terms of profitability, DNLI's ROE is -0.52%, compared to CGON's ROE of -0.23%. Regarding short-term risk, DNLI is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
DNLI vs CNTA Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CNTA's P/E ratio is -22.63. In terms of profitability, DNLI's ROE is -0.52%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DNLI is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
DNLI vs XENE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, XENE has a market cap of 6.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while XENE trades at $64.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas XENE's P/E ratio is -13.62. In terms of profitability, DNLI's ROE is -0.52%, compared to XENE's ROE of -0.49%. Regarding short-term risk, DNLI is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
DNLI vs LGND Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while LGND trades at $300.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas LGND's P/E ratio is 36.07. In terms of profitability, DNLI's ROE is -0.52%, compared to LGND's ROE of +0.16%. Regarding short-term risk, DNLI is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check LGND's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
DNLI vs PTCT Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while PTCT trades at $69.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas PTCT's P/E ratio is -29.66. In terms of profitability, DNLI's ROE is -0.52%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, DNLI is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
DNLI vs SRRK Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while SRRK trades at $47.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas SRRK's P/E ratio is -13.31. In terms of profitability, DNLI's ROE is -0.52%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, DNLI is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
DNLI vs CDTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DNLI's ROE is -0.52%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, DNLI is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
DNLI vs ABCM Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DNLI's ROE is -0.52%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DNLI is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
DNLI vs ISEE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DNLI's ROE is -0.52%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DNLI is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
DNLI vs APLS Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas APLS's P/E ratio is 38.35. In terms of profitability, DNLI's ROE is -0.52%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DNLI is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
DNLI vs TVTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while TVTX trades at $56.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas TVTX's P/E ratio is -254.64. In terms of profitability, DNLI's ROE is -0.52%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, DNLI is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check TVTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
DNLI vs CRSP Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CRSP trades at $53.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CRSP's P/E ratio is -10.39. In terms of profitability, DNLI's ROE is -0.52%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, DNLI is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check CRSP's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
DNLI vs DYN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, DYN has a market cap of 4.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while DYN trades at $25.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas DYN's P/E ratio is -8.07. In terms of profitability, DNLI's ROE is -0.52%, compared to DYN's ROE of -0.64%. Regarding short-term risk, DNLI is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check DYN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
DNLI vs EWTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while EWTX trades at $44.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas EWTX's P/E ratio is -26.93. In terms of profitability, DNLI's ROE is -0.52%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, DNLI is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
DNLI vs TERN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas TERN's P/E ratio is -51.41. In terms of profitability, DNLI's ROE is -0.52%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DNLI is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
DNLI vs ACAD Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ACAD has a market cap of 4.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ACAD trades at $27.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ACAD's P/E ratio is 13.31. In terms of profitability, DNLI's ROE is -0.52%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, DNLI is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check ACAD's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
DNLI vs DFTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while DFTX trades at $42.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas DFTX's P/E ratio is N/A. In terms of profitability, DNLI's ROE is -0.52%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, DNLI is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check DFTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
DNLI vs DNTH Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while DNTH trades at $110.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas DNTH's P/E ratio is -26.73. In terms of profitability, DNLI's ROE is -0.52%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, DNLI is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check DNTH's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
DNLI vs CAI Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CAI trades at $16.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CAI's P/E ratio is -88.56. In terms of profitability, DNLI's ROE is -0.52%, compared to CAI's ROE of +0.06%. Regarding short-term risk, DNLI is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CAI's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
DNLI vs FOLD Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DNLI's ROE is -0.52%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DNLI is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check FOLD's competition here
Celcuity Inc. (NASDAQ: CELC)
DNLI vs CELC Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CELC trades at $92.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CELC's P/E ratio is -23.72. In terms of profitability, DNLI's ROE is -0.52%, compared to CELC's ROE of -2.45%. Regarding short-term risk, DNLI is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check CELC's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
DNLI vs AKRO Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DNLI's ROE is -0.52%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, DNLI is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check AKRO's competition here
Veradermics, Incorporated (NYSE: MANE)
DNLI vs MANE Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while MANE trades at $107.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas MANE's P/E ratio is -34.17. In terms of profitability, DNLI's ROE is -0.52%, compared to MANE's ROE of -0.84%. Regarding short-term risk, DNLI is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check MANE's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
DNLI vs ALPN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DNLI's ROE is -0.52%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DNLI is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
DNLI vs ELVN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ELVN trades at $61.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ELVN's P/E ratio is -36.59. In terms of profitability, DNLI's ROE is -0.52%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, DNLI is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
DNLI vs OPT Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, DNLI's ROE is -0.52%, compared to OPT's ROE of +1.18%. Regarding short-term risk, DNLI is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
DNLI vs PRTC Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas PRTC's P/E ratio is -3.78. In terms of profitability, DNLI's ROE is -0.52%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, DNLI is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
DNLI vs MRTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DNLI's ROE is -0.52%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DNLI is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check MRTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
DNLI vs ADPT Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ADPT trades at $24.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ADPT's P/E ratio is -45.46. In terms of profitability, DNLI's ROE is -0.52%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, DNLI is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check ADPT's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
DNLI vs CPRX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CPRX's P/E ratio is 12.30. In terms of profitability, DNLI's ROE is -0.52%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DNLI is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CPRX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
DNLI vs VKTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while VKTX trades at $32.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas VKTX's P/E ratio is -7.96. In terms of profitability, DNLI's ROE is -0.52%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, DNLI is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check VKTX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
DNLI vs RYZB Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DNLI's ROE is -0.52%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DNLI is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
DNLI vs CBAY Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DNLI's ROE is -0.52%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DNLI is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check CBAY's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
DNLI vs ORKA Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, ORKA has a market cap of 3.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while ORKA trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas ORKA's P/E ratio is -50.58. In terms of profitability, DNLI's ROE is -0.52%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, DNLI is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check ORKA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
DNLI vs TNGX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while TNGX trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas TNGX's P/E ratio is -35.37. In terms of profitability, DNLI's ROE is -0.52%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, DNLI is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for DNLI.Check TNGX's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
DNLI vs RCUS Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, RCUS has a market cap of 3.6B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while RCUS trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas RCUS's P/E ratio is -8.85. In terms of profitability, DNLI's ROE is -0.52%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, DNLI is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
DNLI vs SWTX Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas SWTX's P/E ratio is -13.78. In terms of profitability, DNLI's ROE is -0.52%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, DNLI is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check SWTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
DNLI vs LEGN Comparison August 2026
Denali Therapeutics Inc. (NASDAQ: DNLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 3.8B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, DNLI is priced at $24.17 on the NASDAQ, while LEGN trades at $19.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -8.39, whereas LEGN's P/E ratio is -28.13. In terms of profitability, DNLI's ROE is -0.52%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, DNLI is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for DNLI.Check LEGN's competition here